David Malcom Rodman - 14 Jul 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
14 Jul 2025
Net transactions value
-$159,022
Form type
4
Filing time
15 Jul 2025, 17:00:35 UTC
Previous filing
16 Jun 2025
Next filing
14 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rodman David Malcom Chief Medical Officer 150 N. RADNOR CHESTER ROAD,, SUITE F200, RADNOR /s/ Adam Levy, Attorney-in-fact 15 Jul 2025 0001672659

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $6,857 +6,349 +6.2% $1.08 109,273 14 Jul 2025 Direct F1, F2
transaction MLYS Common Stock Sale $165,879 -11,366 -10% $14.59 97,907 14 Jul 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -6,349 -6.7% $0.000000 88,880 14 Jul 2025 Common Stock 6,349 $1.08 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.
F2 This balance includes 1,273 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.0700 to $14.7594. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.